"Multiprofile Hospital for Active Treatment of Neurology and Psychiatry - Sveti Naum" EAD - Neurology Clinic for Movement Disorders
Welcome,         Profile    Billing    Logout  
 82 Trials 
83 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Investigator, Principal
NCT04790279: Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

Recruiting
4
160
US
Amlodipine, NIFEdipine ER
Prisma Health-Upstate
Hypertension in Pregnancy
10/22
10/22
NCT04459377 / 2014-004235-39: Ketamine Analgesia in Third Molar Surgery

Recruiting
4
165
Europe
S-Ketamine, Sodium Chloride 0.9% Inj
Dalarna County Council, Sweden, Uppsala University, Center for Clinical Research Dalarna, Sweden
Pain, Postoperative
12/22
12/23
OCEAN, NCT04986982: OpiCapone Effect on Motor Fluctuations and pAiN

Recruiting
4
140
Europe
Opicapone 50 mg, BIA 9-1067, Matching placebo
Bial - Portela C S.A.
Parkinson Disease
12/22
12/22
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy

Recruiting
4
100
US
Ketamine
University of Oklahoma
Hemorrhoids
01/23
07/23
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Not yet recruiting
4
268
RoW
Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox
Daiichi Sankyo, Inc.
COPD Exacerbation Acute
06/23
06/23
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Recruiting
4
60
US
Tamsulosin Hydrochloride
Feiran Lou, UMass Memorial Health Care
Thoracic Diseases, Urinary Retention
06/23
12/23
TROPION-LUNG01, NCT04656652 / 2020-004643-80: Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations

Checkmark [VIRTUAL] TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).
Checkmark [VIRTUAL] A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).
Recruiting
3
590
Europe, Canada, Japan, US, RoW
DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel
Daiichi Sankyo, Inc., AstraZeneca
Non-small Cell Lung Cancer
09/23
06/24
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Recruiting
3
300
Europe, Canada, US, RoW
Macitentan, ACT-064992, Standard-of-care
Actelion
Pulmonary Arterial Hypertension
02/24
02/24
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Calendar Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
Jul 2021 - Jul 2021: First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, Inc., AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
04/24
11/24
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC

Not yet recruiting
3
632
RoW
docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy
Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Fourth Military Medical University, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
06/24
06/26
HERTHENA-Lung02, NCT05338970: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Recruiting
3
560
Europe, Canada, Japan, US, RoW
Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy
Daiichi Sankyo, Inc.
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
08/24
08/26
frontMIND, NCT04824092 / 2020-002990-84: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Calendar Jul 2025 - Dec 2025: Primary analysis data from frontMIND trial in combination with Revlimid for newly diagnosed DLBCL
Checkmark frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.
Checkmark First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at EHA 2021
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at ASCO 2021
More
Recruiting
3
880
Europe, Canada, US, RoW
Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
MorphoSys AG, MorphoSys AG
Diffuse Large B-cell Lymphoma
06/25
05/26
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Calendar Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Checkmark Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05)
Recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, Inc., AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
09/27
Tropion-Lung08, NCT05215340 / 2021-002555-10: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Checkmark Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non–small cell lung cancer (NSCLC) with PD-L1 ≥ 50% and without actionable genomic alterations.
Recruiting
3
740
Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab
Daiichi Sankyo, Inc., AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
06/26
06/26
KPL-716-C201, NCT03816891 / 2020-004198-38: Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Recruiting
2a/b
230
Europe, Canada, US, RoW
vixarelimab, KPL-716, Placebo
Kiniksa Pharmaceuticals, Ltd.
Prurigo Nodularis, Pruritis
11/22
07/23
LOMBARD, NCT04583358 / 2020-000047-31: Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis

Recruiting
2a
102
Europe, Canada, US, RoW
AMT-101 (oral), Placebo (oral)
Applied Molecular Transport
Ulcerative Colitis
06/22
06/22
ESTRELLA, NCT04764448 / 2020-003313-35: A Study of Belcesiran in Patients With A1ATD-Associated Liver Disease

Checkmark [VIRTUAL] BELCESIRAN WAS WELL-TOLERATED AND REDUCED SERUM AAT LEVELS IN HEALTHY VOLUNTEERS (PHASE 1 INTERIM RESULTS)
Recruiting
2a
54
Europe, Canada, RoW
belcesiran, Placebo
Dicerna Pharmaceuticals, Inc.
Alpha 1-Antitrypsin Deficiency
12/22
12/23
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Recruiting
2
95
US
RGX-314 Dose 1, RGX-314 Dose 2, Ranibizumab (LUCENTIS®), RGX-314 Dose 3
Regenxbio Inc.
Neovascular Age-Related Macular Degeneration (nAMD)
03/23
06/23
StrataSOMA, NCT04765202: StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

Recruiting
2
40
US
AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA)
Stratatech, a Mallinckrodt Company
Full Thickness Burn
06/23
06/23
HERTHENA-Lung01, NCT04619004 / 2020-000730-17: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Checkmark Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
Checkmark [VIRTUAL] Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Checkmark [VIRTUAL] HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Recruiting
2
420
Europe, Japan, US, RoW
Patritumab Deruxtecan (Fixed dose), U3-1402, HER3-DXd, Patritumab Deruxtecan (Up-Titration)
Daiichi Sankyo, Inc., Daiichi Sankyo Co., Ltd.
Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
11/23
07/24
NCT05198310: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Recruiting
2
99
US
KPL-404, Placebo
Kiniksa Pharmaceuticals, Ltd.
Arthritis, Rheumatoid
12/23
03/24
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)

Not yet recruiting
2
25
RoW
CST-103, CST-107, matching placebo
CuraSen Therapeutics, Inc.
Freezing of Gait Symptoms in Parkinson's Disease
12/23
03/24
NCT04703192 / 2020-004954-31: Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Checkmark A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL), Including R/R Adult T-Cell Leukemia/Lymphoma (ATL) – Valentine-PTCL01
Checkmark Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma
Checkmark [VIRTUAL] FIRST-IN-HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS-3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS
Recruiting
2
176
Europe, Canada, Japan, US, RoW
Valemetostat Tosylate, DS-3201b
Daiichi Sankyo, Inc.
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
12/23
03/26
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Not yet recruiting
2
100
RoW
Tis-U-Sol
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Nasopharyngeal Neoplasms
05/24
05/26
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Checkmark A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.
Checkmark Transcriptomics-based stratification of response to MAPK inhibition in vitro better predicts sensitivity to single agent and combination treatment than MAPK genomic alteration status alone
Checkmark ASTX029, a Novel Dual-Mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK.
Checkmark ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics
Checkmark [VIRTUAL] Immune modulation by the dual-mechanism ERK inhibitor, ASTX029, in MAPK-activated tumor models
More
Recruiting
1/2
300
Europe, US
ASTX029
Astex Pharmaceuticals, Inc.
Solid Tumor, Adult
06/23
12/23
NCT05205330: A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients

Recruiting
1/2
27
Europe
CR6086, AGEN2034, Balstilimab
Rottapharm Biotech, Agenus Inc.
Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient
06/23
12/24
EPCORE NHL-1, NCT03625037 / 2017-001748-36: GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Checkmark PRIMARY RESULTS OF SUBCUTANEOUS EPCORITAMAB DOSE EXPANSION IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A PHASE 2 STUDY
Checkmark Phase 3 Trial (EPCORE DLBCL-1) of Epcoritamab Versus Standard of Care in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Checkmark Subcutaneous Epcoritamab in Combination with R2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial
Checkmark Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial
Checkmark Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial
More
Recruiting
1/2
486
Europe, Canada, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3xCD20
Genmab, AbbVie
Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
10/23
07/25
NCT03793478 / 2016-002919-18: Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Checkmark A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
Recruiting
1/2
65
Europe, Canada, US, RoW
Quizartinib, Quizartinib dihydrochloride, Vanflyta, Intrathecal (IT) triple chemotherapy prophylaxis, Fludarabine, Cytarabine, Etoposide
Daiichi Sankyo, Inc., Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group
Acute Myeloid Leukemia
05/27
05/27
KEYNOTE KN-797, NCT04042701: DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Checkmark [VIRTUAL] Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study
Checkmark [VIRTUAL] Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.
Recruiting
1b
115
Europe, US
Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
Daiichi Sankyo, Inc., AstraZeneca UK Limited, Merck Sharp & Dohme LLC
Breast Cancer, Non-small Cell Lung Carcinoma
08/22
05/23
KEYNOTE KN-B43, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Checkmark TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
Checkmark Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non–small cell lung cancer (NSCLC) with PD-L1 ≥ 50% and without actionable genomic alterations.
Checkmark [VIRTUAL] TROPION - Lung02: Datopotamab Deruxtecan (Dato - DXd) Plus Pembrolizumab and Platinum - Based Chemotherapy in Advanced NSCLC
Recruiting
1b
120
Europe, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, Pembrolizumab, Carboplatin, Cisplatin
Daiichi Sankyo, Inc., AstraZeneca, Merck Sharp & Dohme LLC
Advanced or Metastatic NSCLC
12/22
10/24
NCT04953897: Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Recruiting
1b
18
Europe
ASTX727, Oral decitabine and cedazuridine
Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
01/23
01/23
NCT04953910: Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Recruiting
1b
27
Europe
ASTX727, Oral decitabine and cedazuridine
Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
12/24
12/24
NCT04099771: Ketamine for Mood Disorders With Suicidal Ideation

Recruiting
1
20
US
Ketamine
The Miriam Hospital
Depressive Disorder, Major, Suicidal Ideation
12/21
12/21
NCT03260491: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Checkmark Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
Checkmark [VIRTUAL] Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Checkmark [VIRTUAL] Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
Checkmark Data from trial for NSCLC
Jan 2021 - Jan 2021: Data from trial for NSCLC
More
Recruiting
1
264
Europe, Japan, US, RoW
U3-1402 (FL-DP), U3-1402 (CTM-1 Lyo-DP), U3-1402 (CTM-3 Lyo-DP)
Daiichi Sankyo, Inc.
Non-Small Cell Lung Cancer (NSCLC)
01/22
12/23
NCT05429840: Safety & PK of Single Doses of MT1980

Recruiting
1
32
Europe
MT1980, Placebo
Monument Therapeutics Limited, ICON plc
Neuroinflammatory Response
11/22
11/22
NCT04894110: Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Recruiting
1
18
US
EO2002
Emmecell
Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation
12/22
06/23
NCT05203692: A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

Recruiting
1
80
US
DS-7011a, Placebo
Daiichi Sankyo, Inc.
Systemic Lupus Erythematosus
12/22
12/22
NCT05484414: Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)

Recruiting
1
56
US
SRP-3D (diethylamide), SRP-3D (DA), Placebo, Control
South Rampart Pharma, LLC
Pain
03/23
03/23
NCT04528836: First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

Recruiting
1
130
US
BBP-398 (Formerly known as IACS-15509)
Navire Pharma Inc., a BridgeBio company
Tumor, Solid
04/23
10/23
NCT05388903: A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

Recruiting
1
64
US
DS-2325a, Placebo
Daiichi Sankyo, Inc.
Netherton Syndrome
04/23
04/23
NCT04707248: A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Checkmark Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC).
Checkmark [VIRTUAL] DS-6000a, a novel CDH6-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
Recruiting
1
102
Japan, US
DS-6000a
Daiichi Sankyo, Inc.
Renal Cell Carcinoma, Ovarian Tumor
05/23
07/23
ICVP, NCT04634383: A Phase I Feasibility Study of an Intracortical Visual Prosthesis () for People With Blindness

Recruiting
1
5
US
WFMA - wireless floating microelectrode array, ICVP System, ICVP, Intracortical Visual Prosthesis
Illinois Institute of Technology, National Institute of Neurological Disorders and Stroke (NINDS), Rush University Medical Center, The Chicago Lighthouse, The University of Texas at Dallas, University of Chicago, Johns Hopkins University
Ocular Injury, Optic Nerve Diseases, Photoreceptor Degeneration, Blindness,Acquired
08/23
08/23
NCT05394675: A Study of DS-9606a in Patients With Advanced Solid Tumors

Recruiting
1
125
US
DS-9606a
Daiichi Sankyo, Inc.
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Germ Cell Tumor
11/23
11/23
NCT05029960: Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

Recruiting
1
30
US
Brivaracetam
University of Rochester
Brain Tumor
12/23
12/23
NCT04676477: Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Checkmark Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC.
Checkmark Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402).
Recruiting
1
252
Japan, US
Patritumab deruxtecan, U3-1402, HER3-DXd, Osimertinib
Daiichi Sankyo, Inc.
Non-Small Cell Lung Cancer (NSCLC)
01/24
01/24
SQ3370-001, NCT04106492: Phase 1 Study of SQ3370 in Patients With Advanced Solid Tumors

Checkmark Click activated protodrugs against cancer (CAPAC™): A modular platform for tumor-directed oncology therapeutics | Poster Board #2866
Checkmark Interim phase 1 results for SQ3370 in advanced solid tumors.
Checkmark SQ3370 in advanced solid tumors: Interim phase 1 results
Checkmark Click Activated Protodrugs Against Cancer (CAPAC™): A modular platform for tumor directed oncology therapeutics
Checkmark Combination of click chemistry-based SQ3370 with immunotherapies enhances antitumor effect in murine tumors with minimized systemic toxicity
More
Recruiting
1
110
US, RoW
SQ3370
Shasqi, Inc.
Cancer
08/24
07/26
TROPION-PanTumor01, NCT03401385: First-in-human Study of DS-1062a for Advanced Solid Tumors

Checkmark TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
Checkmark Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non–small cell lung cancer (NSCLC) with PD-L1 ≥ 50% and without actionable genomic alterations.
Checkmark Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study
Checkmark [VIRTUAL] Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study
Checkmark [VIRTUAL] TROPION - PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors
More
Recruiting
1
770
Japan, US
Datopotamab Deruxtecan (Dato-DXd), DS1062a, Study treatment
Daiichi Sankyo Co., Ltd., Daiichi Sankyo, Inc., AstraZeneca
Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
01/25
01/25
NCT02454296: Paracervical Block for Pain Associated With Laminaria Insertion

Checkmark Paracervical Block for Laminaria Insertion Before Second-Trimester Abortion: A Randomized Controlled Trial.
Recruiting
N/A
40
US
Paracervical Block with lidocaine, Paracervical block, Sham paracervical block, Sham block; placebo
University of Hawaii
Pain
12/15
12/15
NCT04445207: Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

Available
N/A
US
Convalescent Plasma
Jonathan Gerber
COVID, Sars-CoV2, Corona Virus Infection
 
 
NCT04886544: Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring

Active, not recruiting
N/A
72
Europe
YVOIRE Y-Solution 720
LG Chem
Jaw Volume Deficit
05/22
11/22
NCT03586414: MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women

Recruiting
N/A
60
US
MITOQUINOL MESYLATE then placebo, MitoQ, Mitoquinol methanesulfonate, Placebo, then MITOQUINOL MESYLATE
University of Colorado, Denver, University of Colorado Nutrition Obesity Research Center (NORC)
Diastolic Dysfunction
07/22
08/22
NCT05133973: Feasibility Study of a Transdermal Continuous Glucose Monitoring (CGM) System in Diabetic Patients

Not yet recruiting
N/A
12
Europe
FiberSense CGM
EyeSense GmbH
Diabetes
08/22
09/22
NCT03866707: Epigenetic and Metabolomic Changes in Childhood Cancer Survivors

Recruiting
N/A
16
US
One-time blood draw, Evaluation of CpG methylation, Metabolomic analysis
Wake Forest University Health Sciences
Childhood Cancer
09/22
09/22
TMSVS, NCT04925232: Transcranial Magnetic Stimulation For Visual Snow Syndrome

Checkmark A Study Protocol for an Open-Label Feasibility Treatment Trial of Visual Snow Syndrome With Transcranial Magnetic Stimulation.
Active, not recruiting
N/A
10
US
Transcranial Magnetic Stimulation device, TMS
University of Colorado, Denver
Visual Snow Syndrome
11/22
11/22
B-Free, NCT03928236: Benzodiazepine-free Cardiac Anesthesia for Reduction of Postoperative Delirium

Recruiting
N/A
15886
Canada
Limited Intraoperative Benzodiazepine, Liberal Intraoperative Benzodiazepine
Population Health Research Institute
Delirium, Post-cardiac Surgery
12/22
06/23
ACAB, NCT04292405: Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator

Recruiting
N/A
60
US
Wearable Cardioverter Defibrillator, AUDICOR AM
Zoll Medical Corporation
Heart Failure
12/22
03/23
NCT04622969: The Healthy Child Development Program Study

Recruiting
N/A
60
US
Healthy Child Development Program
University of South Carolina
Child Behavior, Child Health, Child, Preschool, Parents
12/22
02/23
TASCS, NCT04720911: Technology-Assisted Systems Change for Suicide Prevention

Recruiting
N/A
45
US
In-person TASCS, Telehealth TASCS, Self-administered TASCS, Follow-up care
University of Massachusetts, Worcester, National Institute of Mental Health (NIMH), Worcester Polytechnic Institute
Suicide, Suicide, Attempted
12/22
12/22
NCT04625660: Detour2 Continued Access Study

Recruiting
N/A
70
US
PQ Bypass System
PQ Bypass, Inc.
Peripheral Artery Diseases
01/23
01/24
NCT04049591: Higher vs. Lower Dose Heparin for PCI

Not yet recruiting
N/A
16000
Canada
Higher Dose UFH, Lower Dose UFH
Population Health Research Institute
Cardiovascular Diseases, Percutaneous Coronary Intervention
01/23
05/23
PAROS, NCT04745520: Randomized Clinical Trial of Rib Fixation Versus Medical Analgesia in Uncomplicated Rib Fractures on Pain Control.

Recruiting
N/A
102
Europe
Rib fixation, Analgesia
Benoît Bédat, Centre Hospitalier Universitaire Vaudois, Hôpital du Valais
Rib Fractures
03/23
03/24
NCT05120895: An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia

Recruiting
N/A
1237
RoW
Mevalotin
Daiichi Sankyo, Inc., Daiichi Sankyo Korea Co., Ltd.
Dyslipidemia
04/23
04/23
MNH, NCT01073475: Maternal Newborn Health Registry

Checkmark Stillbirth 2010-2018: a prospective, population-based, multi-country study from the Global Network.
Checkmark Neonatal deaths in rural Karnataka, India 2014-2018: a prospective population-based observational study in a low-resource setting.
Checkmark The Global Network Maternal Newborn Health Registry: a multi-country, community-based registry of pregnancy outcomes.
Checkmark Evaluating the effect of care around labor and delivery practices on early neonatal mortality in the Global Network's Maternal and Newborn Health Registry.
Checkmark The relationship between birth intervals and adverse maternal and neonatal outcomes in six low and lower-middle income countries.
More
Recruiting
N/A
950000
US, RoW
There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.
NICHD Global Network for Women's and Children's Health
Pregnancy Outcome Trends in Low-resource Geographic Areas
05/23
05/23
NCT03929731: Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)

Recruiting
N/A
72
RoW
Indocyanine Green Angiography, Optical Coherence Tomography-Angiography, Fundus photography, Fundus fluorescein, Optical Coherence Tomography
Singapore National Eye Centre
Polypoidal Choroidal Vasculopathy
06/23
06/23
NCT04931251: Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings

Recruiting
N/A
780
US
Financial Navigation
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Neoplasms, Carcinoma
06/23
07/23
BHmApp, NCT04074044: Evaluation of a New Bladder Health Mobile Application in Pregnancy

Recruiting
N/A
30
US
BHmApp
William Beaumont Hospitals, University of Pennsylvania
Urinary Incontinence
09/23
09/24
MEE, NCT04730700: Evaluation of Multi-Tined Expandable Electrode () Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management.

Recruiting
N/A
50
US
Radiofrequency Ablation with MEE, Conventional Medical Management
University of Kansas Medical Center
Chronic Low-back Pain
11/23
11/23
NCT04910048: Impact of a POPOP on Preoperative Health, Eligibility, and Clinical & Patient-Reported Outcomes in TJA

Recruiting
N/A
70
US
POPOP (preoperative patient optimization program), 20Lighter, SOC (standard of care)
University of Arkansas
Osteoarthritis, Knee, Osteoarthritis, Hip, Avascular Necrosis, Rheumatoid Arthritis
01/24
01/24
NCT02945085: 3D Team Care for Cognitively Vulnerable Older Adults

Checkmark Pharmacist Identification of Medication Therapy Problems Involving Cognition Among Older Adults Followed by a Home-Based Care Team.
Recruiting
N/A
956
US
Home Based Care Team, Telephone Based Care Team
UConn Health, Patient-Centered Outcomes Research Institute, University of Connecticut
Dementia, Depression, Delirium
07/24
07/24
LEARN, NCT05242952: The Study for CVD Prevention

Checkmark Cardiovascular Disease Prevention Education Using a Virtual Environment in Sexual-Minority Men of Color With HIV: Protocol for a Sequential, Mixed Method, Waitlist Randomized Controlled Trial.
Recruiting
N/A
80
US
Gaming in a virtual environment
Yale University, National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Diseases
07/24
07/24
NCT04927052: A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment

Recruiting
N/A
140
Canada
Revanesse Shape + with Lidocaine, Juvederm Voluma with Lidocaine.
Prollenium Medical Technologies Inc.
Volume Deficit in the Mid-face
08/24
08/24
ETNA-AF-CHINA, NCT04747496: Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

Recruiting
N/A
5000
RoW
Edoxaban
Daiichi Sankyo, Inc., Daiichi Sankyo (China) Holdings Co., Ltd.
Non-valvular Atrial Fibrillation
08/24
08/24
NCT01336790: International Lymphatic Disease and Lymphedema Registry

Recruiting
N/A
5000
US
Stanford University, Lymphatic Education & Research Network
Lymphedema
12/24
12/25
NCT04258280: Improving Genetic Counseling for BRCA+ Mothers

Recruiting
N/A
200
US
Education and counseling, Education
Georgetown University
Breast Cancer
12/24
12/25
NCT03843190: Healthy Me: A Program for Older Women

Recruiting
N/A
240
US
Take of Pounds Sensibly (TOPS)
Duke University
Obesity
03/25
03/25
NCT04635111: A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Recruiting
N/A
30
US
TURALIO™
Daiichi Sankyo, Inc.
Hepatotoxicity, Tenosynovial Giant Cell Tumor
06/25
03/36
RELIEF, NCT04100135: GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

Recruiting
N/A
150
US
Actual device PFO closure, GORE® CARDIOFORM Septal Occluder, Thienopyridine (clopidogrel or prasugrel), Plavix, Effient, Sham device PFO closure
W.L.Gore & Associates
Migraine, Patent Foramen Ovale
12/25
08/27
NCT05022862: Economic Incentives and vDOT for Latent Tuberculosis Infection

Recruiting
N/A
399
US
Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives
Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID)
Latent Tuberculosis
04/26
10/26
NCT05181163: Biofilm Formation and Antibiotic Sensitivity Patterns

Not yet recruiting
N/A
100
NA
swab
Sohag University
Orthopedic Surgery
07/22
01/23
CHIRP, NCT05218824: Collection of Head Images During Radiotherapy

Not yet recruiting
N/A
30
RoW
University of Sydney, Western Sydney Local Health District
Head and Neck Neoplasms, Radiation Therapy Complication
02/23
02/23
EUROPA T-DXd, NCT05458401: EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

Not yet recruiting
N/A
200
Europe
Trastuzumab deruxtecan, T-DXd
Daiichi Sankyo, Inc.
HER2-positive Breast Cancer
04/23
04/23
ROCK-RT, NCT05169177: Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy: An Observational Feasibility Study

Not yet recruiting
N/A
50
RoW
University of Sydney, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia, Princess Alexandra Hospital, Brisbane, Australia
Liver Neoplasm
01/24
01/26
LEARN, NCT05184790: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Not yet recruiting
N/A
300
RoW
University of Sydney, Princess Alexandra Hospital, Brisbane, Australia, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia
Arrhythmias, Cardiac, Breast Cancer, Prostatic Cancer, Brain Cancer, Kidney Cancer, Head and Neck Cancer, Liver Cancer, Pancreatic Cancer, Spinal Neoplasm
01/25
01/25

Download Options